Therapeutic Comparision Of Recombinant Human B-type Natriuretic Peptide Vs Isosorbide Dinitrate In The Patients With Acute Decompensated Heart Failure

ObjectiveCompared the comprehensive therapeutic effect of the recombinant B-type natriuretic peptide with isosorbide dinitrate in treating the patients with acute decompensated heart failure; Compared the clinical manifestations of the recombinant B-type natriuretic peptide with isosorbide dinitrate in treating the patients with acute decompensated heart failure; In the acute decompensated stage of heart failure, temporarily intravenous rh-BNP compared the quality of life of the patients with isosorbide dinitrate;Compared the side effects of the recombinant B-type natriuretic peptide with isosorbide dinitrate in treating acute heart failure.MethodsChose 39 patients who were hospitalized in the geriatric department of the Second Xiangya Hospital from March 2009 to February 2010,which were diagonosed as the acute decompensated heart failure with clinical materials and the NT-proBNP test,Randomly divided them as two teams,20 patients treating with the standard therapy and the recombinant huaman B-type natriuretic peptide,which first loading dose intravenous injection and then sustaining with minute dose intravenous pumping; and 19 patients treating with the standard therapy and the isosorbide dinitrate therapy. Evaluated the clinical manifestations such as dyspnea,pulmonary rale, edema in lower extremities and urine quantity for the two teams in pretherapy and post-treatment;Evaluated the side effects during the treatment and post-treatment. All patients finished the Minnesota Living with Heart Failure questionnaire(MLHFQ) on the day before therapy. The patients whose symptoms has obviously improved wrote the MLHFQ again one month later.ResultsThe basic materials of the two teams was not significantly different,so the two teams were comparable.The clinical manifestations such as dyspnea and pulmonary rale improved more obviously in the recombinant human B-type natriuretic peptide team than the isosorbide dinitrate team(P<0.05).The improvement of the edema in lower extremities was not obviously different in the two teams (P>0.05). The adding urine in the rh-BNP was obviously more than the quantity in the isosorbide dinitrate.After one month, the decreasing score of MLHFQ in the rh-BNP was significantly different than the score in the isosorbide dinitrate. For the hypotension,there was no significant difference in the two teams.Conclusions:1. The recombinant human B-type natriuretic peptide could rapidly and effectively improved the symptoms and signs of the patients with the acute decompensated heart failure and their quality of life.2. The recombinant human B-type natriuretic peptide was safe in treating patients with the acute decompensated heart failure.